As a primary implant for patients who present with eye disease or severe damage such that the eye must be enucleated or eviscerated. An existing orbital implant that is malfunctioning or not satisfying the patient in terms of performance, may call for a secondary implant procedure to install a bio-ceramic orbital implant.
Device Story
Bioceramic orbital implant; used as primary or secondary ocular implant following enucleation or evisceration. Device serves as structural replacement for removed eye; provides volume to orbital cavity; supports ocular prosthesis. Implanted surgically by ophthalmologist/surgeon in clinical setting. Bioceramic material promotes tissue integration; reduces risk of migration or extrusion compared to non-integrated implants. Patient benefits include improved cosmetic outcome and prosthetic motility.
Clinical Evidence
No clinical data provided; substantial equivalence determination based on device description and intended use.
Technological Characteristics
Bioceramic material; spherical or porous form factor designed for orbital implantation; biocompatible; non-resorbable; intended for surgical placement.
Indications for Use
Indicated for patients requiring enucleation or evisceration due to eye disease or severe damage, and for patients requiring secondary implant procedures due to malfunction or dissatisfaction with an existing orbital implant.
Regulatory Classification
Identification
An eye sphere implant is a device intended to be implanted in the eyeball to occupy space following the removal of the contents of the eyeball with the sclera left intact.
Special Controls
*Classification.* Class II (special controls). The device, when it is an ocular peg which is supplied sterile only, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.
Related Devices
K023400 — FCI MESH WRAPPED BIOCERAMIC ORBITAL IMPLANT · Fci Ophthalmics, Inc. · Aug 22, 2003
K110554 — BIOCERAMIC ORBITAL IMPLANT, ORBTEX · Ceramisys, Ltd. · Nov 2, 2011
K972143 — MOA BONE / M-SPHERE · Iop, Inc. · Oct 16, 1997
K982562 — BIO-EYE HYDROXYAPATITE OCULAR IMPLAND AND CONFORMER · Integrated Orbital Implants, Inc. · Dec 28, 1998
K073293 — DURETTE IMPLANT · Oculo Plastik, Inc. · Mar 19, 2008
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is an abstract symbol resembling a stylized caduceus or a bird-like figure with three curved lines representing wings or snakes.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
## APR 1 9 2000
FCI Ophthalmics, Inc. c/o Hillard W. Welch Consultant for FCI Ophthalmics, Inc. 344 Annabelle Point Road Centreville, MA 02632-2402
Re: K992294/S4 Bioceramic Orbital Implant Regulatory Class: II Product Code: HPZ Dated: January 25, 2000 Received: January 27, 2000 Amended: February 15, February 25, March 20, March 30, April 4, April 10, April 17, 2000
Dear Mr. Welch:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic OS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{1}------------------------------------------------
## Page 2 - Mr. Hillard Welch
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
A. Ralph Rosenthal
A. Ralph Rosenthal, M.D. Director Division of Ophthalmic, Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
510(k) Number (if known):
Device Name: Bio-ceramic Orbital Implant
Indications For Use:
As a primary implant for patients who present with eye disease or severe damage such that the eye must be enucleated or eviscerated.
An existing orbital implant that is malfunctioning or not satisfying the patient in terms of performance, may call for a secondary implant procedure to install a bio-ceramic orbital implant.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Claudius Xausark
(Division Sign-Off)
Division of Ophthalmic Devices
510(k) Number K992294/SH
X Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)
Panel 1
/
Sort by
Ready
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.